Advertisement

Preliminary Studies of Human Cortical 5-HT2 Receptors and Their Involvement in Schizophrenia and Neuroleptic Drug Action

  • G. P. Reynolds
  • M. N. Rossor
  • L. L. Iversen
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 18)

Summary

It is well established that neuroleptic drugs are antagonists of brain dopamine receptors. The role of the reported increase in dopamine receptors (measured as 3H-spiperone binding sites) in post-mortem brain tissue from patients with schizophrenia in the aetiology of the disease is, however, unclear. We have found this increase only in chronically neuroleptic-treated patients, indicating that the increase is probably due to this neuroleptic treatment.

Many neuroleptic drugs have a high affinity for a subgroup of 5-hydroxytryptamine receptors, which have also been implicated in schizophrenia. Using the specific ligand 3H-ketanserin, we find that certain neuroleptics have a higher affinity for these 5-HT2 receptors than for the dopamine D2 site. Although changes in these receptors have been reported in schizophrenic brain tissue we have been unable to find any difference in receptor density in cortical tissue from schizophrenics and control subjects.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennett, J. P., Enna, S.J., Bylund, D. B., Gillin, J. C., Wyatt, R.J., Snyder, S. H.: Neurotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psych. 36, 927–934 (1979).CrossRefGoogle Scholar
  2. Clow, A., Theodorou, A., Jenner, P., Marsden, C.D.: Changes in rat striatal dopamine turnover and receptor activity during one year’s neuroleptic administration. Eur. J. Pharmac. 63, 135–144 (1980).CrossRefGoogle Scholar
  3. Leysen, J. E., Niemegeers, C.J. E., Van Nueten, J. M., Laduron, P. M.: 3H-Ketanserin (R41468), a selective 3H-ligand for serotonin (S2) receptor binding sites. Binding properties, brain distribution and functional role. Mol. Pharmac. 21, 301–304 (1982).Google Scholar
  4. Mackay, A. VP., Bird, E. D., Spokes, E. G., Rossor, M. N., Iversen, L. L., Creese, I., Snyder, S. H.: Dopamine receptors and schizophrenia: drug effect of illness? Lancet ii, 915–916 (1980).Google Scholar
  5. Mackay, A. V. P., Iversen, L. L., Rossor, M., Spokes, E., Bird, E., Arregui, A., Creese, I., Snyder, S. H.: Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psych. 31, 991–997 (1982).CrossRefGoogle Scholar
  6. Owen, F., Crow, T.J., Poulter, M., Cross, A.J., L ongden, A., Riley, G.J.: Increased dopamine-receptor sensitivity in schizophrenia. Lancet ii, 223–225 (1978).Google Scholar
  7. Peroutka, S.J., Lebowitz, R. M., Snyder, S. H.: Two distinct serotonin receptors with different physiological functions. Science 212, 827–829 (1981).CrossRefPubMedGoogle Scholar
  8. Reynolds, G. P., Riederer, P., Jellinger, K., Gabriel, E.: Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacology 20, 1319–1320 (1981).PubMedGoogle Scholar
  9. Reynolds, G. P., Cowey, L., Rossor, M., Iversen, L.L.: Thioridazine is not specific for limbic dopamine receptors. Lancet ii, 499–500 (1982).Google Scholar
  10. Whitaker, P. M., Crow, T.J., Ferrier, I. N.: Tritiated LSD binding in frontal cortex in schizophrenia. Arch. Gen. Psychiatry 38, 278–280 (1981).CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1983

Authors and Affiliations

  • G. P. Reynolds
    • 2
  • M. N. Rossor
    • 1
  • L. L. Iversen
    • 1
  1. 1.MRC Neurochemical Pharmacology Unit and Brain Tissue BankMedical Research Council Centre, Medical SchoolCambridgeUK
  2. 2.MRC Neurochemical Pharmacology UnitMedical Research Council Centre, Medical SchoolCambridgeUK

Personalised recommendations